Mirum Pharma Crushes Q2, Livmarli Leads Growth
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Mirum Pharmaceuticals reports a stellar Q2 2025, with total revenues surging 64% to $128 million, driven by Livmarlis strong sales across Alagille syndrome, PFIC, and international markets. U.S. Livmarli sales hit $57 million, boosted by increased PFIC diagnoses, while international sales reached $31 million, aided by new reimbursement deals. The companys pipeline is robust, with the VISTAS study for PSC wrapping enrollment and data due in Q2 2026, and Phase 2 trials for MRM-3379 in Fragile X syndrome set to begin by year-end. Financially sound with $322 million in cash and positive cash flow, Mirum is well-positioned for future growth and blockbuster potential.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/d5cbd3aa315fd961